Common peptide-based cancer vaccines currently in clinical practice and trials include GV1001 targeting hTERT in pancreatic and NSCLC (non-small-cell lung cancer), IMA901 for renal cell carcinoma, HER2/neu peptide vaccines like NeuVax and GP2 for breast cancer, NY-ESO-1 vaccines for melanoma and ovarian cancer, WT1 vaccines for leukemia and mesothelioma, and MAGE-A3 vaccines for melanoma and NSCLC [115,116,117,118,119,120,121,122,123]. Here, WT1 is linked to melanoma.